DACARBAZINE CAS 4342-03-4 API Active Pharmaceutical Ingredient

Product Description:

Product Name: DACARBAZINE CAS NO: 4342-03-4                                          

Synonyms:

5-(3,3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide;

1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-;

5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide,DTIC;

Chemical & Physical Properties:

Appearance: Yellowish or reddish powder

Assay :≥99.0%

Density: 1.48 g/cm3

Boiling Point: 456.3℃ at 760 mmHg

Melting Point: 199-205℃

Flash Point: 229.7℃

Refractive Index: 1.678

Stability: Stable at room temperature in closed containers under normal storage and handling conditions.

Storage Condition: 2-8℃

Water Solubility: Slightly soluble in water, DMSO and ethanol /n

Safety Information:

RTECS: NI3950000

Safety Statements: S53-S36/37/39-S45

HS Code: 2933290090

WGK Germany: 3

Risk Statements: R45; R46; R20/21/22; R36/37/38

Hazard Codes: T,Xi,Xn

Hazard Declaration: H302 + H312 + H332; H315; H319; H335; H340; H350

Caution Statements: P201; P261; P280; P305 + P351 + P338; P308 + P313

Signal Word: Danger

Symbols: GHS07, GHS08

Dacarbazine (brand names DTIC, DTIC-Dome; also known as DIC or imidazole carboxamide) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma, Hodgkin's lymphoma, sarcoma, and islet cell carcinoma of the pancreas.

Dacarbazine is a member of the class of alkylating agents, which destroy cancer cells by adding an alkyl group (CnH2n+1) to its DNA.

Dacarbazine is normally administered by intravenous infusion (IV) under the immediate supervision of a doctor or nurse. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent.

It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. It belongs to antineoplastic agent. It is clinically used for the treatment of malignant melanoma with being effective in about 20-30% cases. Combination with vincristine and BCNU can further improve the efficacy. In addition, it also has certain efficacy in treating lung squamous cell carcinoma, sarcoma, leiomyosarcoma and fibrosarcoma but with poor efficacy in treating gastrointestinal cancer.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.